Chu I - Search Results

1

Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment.

Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, Webster JD, Hoover S, Simpson RM, Gauldie J, Green JE. Barkan D, et al. Among authors: chu i. Cancer Res. 2010 Jul 15;70(14):5706-16. doi: 10.1158/0008-5472.CAN-09-2356. Epub 2010 Jun 22. Cancer Res. 2010. PMID: 20570886 Free PMC article.

2

Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.

Chu IM, Lai WC, Aprelikova O, El Touny LH, Kouros-Mehr H, Green JE. Chu IM, et al. PLoS One. 2013;8(4):e61125. doi: 10.1371/journal.pone.0061125. Epub 2013 Apr 8. PLoS One. 2013. PMID: 23577196 Free PMC article.

3

GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.

Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE. Chu IM, et al. Oncogene. 2012 Apr 19;31(16):2017-27. doi: 10.1038/onc.2011.382. Epub 2011 Sep 5. Oncogene. 2012. PMID: 21892208 Free PMC article.

4

BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.

Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE. Hoenerhoff MJ, et al. Among authors: chu i. Oncogene. 2009 Aug 27;28(34):3022-32. doi: 10.1038/onc.2009.165. Epub 2009 Jun 22. Oncogene. 2009. PMID: 19543317 Free PMC article.

5

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE. Bennett CN, et al. Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230. Breast Cancer Res. 2012. PMID: 22812567 Free PMC article.

6

BMI1 suffers a degrading experience.

Hoenerhoff M, Chu IM, Green JE. Hoenerhoff M, et al. Cell Cycle. 2011 Jun 15;10(12):1894-5. doi: 10.4161/cc.10.12.15688. Epub 2011 Jun 15. Cell Cycle. 2011. PMID: 21593587 Free PMC article. No abstract available.

7

The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

Chu I, Blackwell K, Chen S, Slingerland J. Chu I, et al. Cancer Res. 2005 Jan 1;65(1):18-25. Cancer Res. 2005. PMID: 15665275

8

Kinase-dead PKB gene therapy combined with hyperthermia for human breast cancer.

Ma N, Szmitko P, Brade A, Chu I, Lo A, Woodgett J, Klamut H, Liu FF. Ma N, et al. Among authors: chu i. Cancer Gene Ther. 2004 Jan;11(1):52-60. doi: 10.1038/sj.cgt.7700655. Cancer Gene Ther. 2004. PMID: 14681726

9

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Chu IM, Hengst L, Slingerland JM. Chu IM, et al. Nat Rev Cancer. 2008 Apr;8(4):253-67. doi: 10.1038/nrc2347. Nat Rev Cancer. 2008. PMID: 18354415 Review.

10

Comparison of strong cation exchange and SDS-PAGE fractionation for analysis of multiprotein complexes.

Das S, Bosley AD, Ye X, Chan KC, Chu I, Green JE, Issaq HJ, Veenstra TD, Andresson T. Das S, et al. Among authors: chu i. J Proteome Res. 2010 Dec 3;9(12):6696-704. doi: 10.1021/pr100843x. Epub 2010 Nov 9. J Proteome Res. 2010. PMID: 20968308 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

645 results

Search Page

Filters